| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
Revenue  | 2,269 | 2,291 | 2,286 | 2,300 | 2,310 | 2,232 | 2,360 | 2,266 | 2,479 | 2,127 | 3,165 | 3,206 | 3,197 | 2,870 | 2,875 | 3,547 | 3,658 | 3,429 | 3,271 | 3,555 | 3,672 | 3,462 | 3,663 | 3,645 | 3,551 | 3,971 | 6,106 | 3,590 | 3,821 | 3,989 | 3,993 | 4,199 | 4,890 | 5,089 | 4,313 | 4,403 | 5,526 | 6,110 | 5,182 | 5,181 | 6,371 | 6,622 | 6,147 |
| Expenses | 1,792 | 1,807 | 1,740 | 1,768 | 1,784 | 1,763 | 1,841 | 1,907 | 2,004 | 1,909 | 2,365 | 2,404 | 2,399 | 2,249 | 2,273 | 2,738 | 2,932 | 2,864 | 3,009 | 2,947 | 3,013 | 2,724 | 2,977 | 2,867 | 2,916 | 3,092 | 2,860 | 2,895 | 3,103 | 3,251 | 3,319 | 3,301 | 4,359 | 3,650 | 3,224 | 3,403 | 3,903 | 4,124 | 3,776 | 3,882 | 4,622 | 4,485 | 4,142 |
| EBITDA | 477 | 484 | 546 | 532 | 526 | 468 | 519 | 359 | 476 | 218 | 800 | 802 | 798 | 621 | 601 | 809 | 726 | 565 | 262 | 608 | 658 | 738 | 686 | 779 | 635 | 879 | 3,246 | 695 | 718 | 738 | 673 | 898 | 532 | 1,439 | 1,089 | 1,000 | 1,623 | 1,986 | 1,407 | 1,299 | 1,749 | 2,137 | 2,005 |
| Operating Profit % | 20 % | 20 % | 23 % | 22 % | 21 % | 20 % | 21 % | 15 % | 17 % | 9 % | 25 % | 24 % | 24 % | 19 % | 20 % | 22 % | 19 % | 16 % | 7 % | 17 % | 17 % | 20 % | 17 % | 20 % | 19 % | 21 % | 22 % | 18 % | 17 % | 17 % | 16 % | 21 % | 10 % | 28 % | 24 % | 22 % | 27 % | 32 % | 26 % | 24 % | 27 % | 31 % | 31 % |
| Depreciation | 76 | 69 | 73 | 74 | 76 | 84 | 86 | 90 | 114 | 122 | 126 | 147 | 144 | 142 | 148 | 154 | 156 | 172 | 172 | 174 | 179 | 173 | 175 | 176 | 175 | 183 | 177 | 177 | 185 | 181 | 182 | 182 | 179 | 180 | 184 | 195 | 205 | 215 | 234 | 229 | 238 | 238 | 302 |
| Interest | 16 | 12 | 13 | 12 | 16 | 14 | 15 | 7 | 10 | 22 | 41 | 13 | 15 | 35 | 36 | 46 | 77 | 89 | 90 | 81 | 83 | 68 | 45 | 27 | 23 | 27 | 30 | 31 | 39 | 34 | 35 | 33 | 28 | 18 | 9 | 20 | 35 | 32 | 25 | 32 | 77 | 85 | 101 |
| Profit Before Tax | 426 | 519 | 545 | 537 | 498 | 441 | 435 | 324 | 412 | 154 | 712 | 722 | 724 | 570 | 535 | 672 | 606 | 394 | 122 | 457 | 522 | 588 | 524 | 617 | 526 | 777 | 3,135 | 598 | 558 | 673 | 648 | 781 | 484 | 1,328 | 1,006 | 947 | 1,550 | 1,900 | 1,271 | 1,184 | 1,672 | 1,921 | 1,687 |
| Tax | 69 | 51 | 60 | 97 | -74 | 36 | 46 | -6 | 20 | 9 | 200 | 168 | 125 | 102 | 107 | 150 | 124 | 69 | 28 | 86 | 108 | 102 | 89 | 89 | -210 | 135 | 123 | 87 | 105 | 96 | 122 | 149 | 125 | 195 | 203 | 157 | 304 | 417 | 351 | 158 | 428 | 400 | 449 |
| Net Profit | 357 | 468 | 485 | 440 | 572 | 405 | 389 | 331 | 393 | 145 | 513 | 553 | 599 | 467 | 428 | 522 | 482 | 325 | 94 | 371 | 414 | 487 | 435 | 528 | 735 | 643 | 3,012 | 511 | 453 | 576 | 526 | 631 | 358 | 1,134 | 803 | 790 | 1,246 | 1,483 | 920 | 1,026 | 1,244 | 1,521 | 1,239 |
| EPS in ₹ | 17.11 | 22.47 | 6.46 | 4.21 | 5.59 | 3.89 | 3.71 | 3.16 | 3.77 | 1.35 | 4.92 | 5.31 | 5.77 | 4.50 | 4.08 | 4.99 | 4.40 | 2.97 | 1.05 | 3.65 | 3.83 | 4.43 | 4.62 | 5.15 | 6.64 | 5.74 | 29.32 | 4.89 | 3.88 | 5.06 | 5.15 | 6.15 | 2.93 | 10.74 | 7.91 | 7.80 | 11.69 | 14.11 | 9.06 | 10.17 | 11.64 | 14.58 | 12.51 |
Zydus Life Science
Zydus Life Science
919.00
-10.15
(-1.09%)
Market Cap
₹92,472.90 Cr
PE Ratio
18.59
Volume
1,80,009.00
Day High - Low
₹929.00 - ₹916.10
52W High-Low
₹1,059.05 - ₹795.00
Key Fundamentals
Market Cap
92,472.90 Cr
EPS
44.97
PB Ratio
3.69
Book Value
251.45
EBITDA
7,328.00
Dividend Yield
1.18 %
Industry
Healthcare Sector
Pharmaceuticals ROE Growth %
-
Debt to Equity
0.09
Analyst Rating and Forecast
- By Refinitiv from28 analysts
Actual
Company News
View All News
Zydus Life Sciences announces postal ballot voting results for special resolution dated December 12, 2025, with remote e-voting conducted through CDSL platform from November 13 to December 12, 2025.
Zydus Lifesciences enters exclusive partnership with Formycon for licensing and supply of biosimilar to Keytruda in the US and Canada markets.
Zydus Lifesciences launched Zyrifa, a Denosumab biosimilar priced at Rs 12,495 MRP, designed to reduce skeletal complications in cancer patients with bone metastases across multiple tumor types including breast, prostate, lung, and kidney cancers. The therapy targets patients experiencing bone metastases, which affects 50-70% of advanced breast or prostate cancer patients and 15-40% of lung, kidney, thyroid, and melanoma cases, aiming to improve mobility and quality of life during cancer treatment.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,784.20 | #1 4,28,089.35 | 41.06 | #1 54,729.00 | 9.71 | #1 10,980 | 2.89 | 56.39 | |
6,392.00 | 1,69,687.52 | 68.66 | 9,712.00 | 18.67 | 2,191 | 35.10 | 49.16 | |
3,775.40 | 1,27,776.69 | 59.93 | 11,539.40 | 6.99 | 1,911 | 30.46 | 59.20 | |
1,510.70 | 1,22,027.41 | 22.55 | 28,409.50 | 7.12 | 5,291 | 3.71 | 49.51 | |
1,271.10 | 1,06,087.76 | 18.62 | 33,741.20 | 16.73 | 5,725 | -0.38 | 59.83 | |
2,087.10 | 95,329.24 | 22.21 | 22,909.50 | 13.74 | 3,306 | #1 72.75 | 65.41 | |
919.00 | #7 92,472.90 | #1 18.59 | #5 23,511.00 | #3 18.55 | #4 4,615 | #3 34.60 | 42.49 | |
2,152.90 | 88,862.78 | 50.72 | 12,744.20 | #1 20.90 | 2,007 | -21.05 | 34.32 | |
1,185.60 | 68,859.84 | 20.27 | 32,345.60 | 9.43 | 3,484 | 3.81 | 52.36 | |
5,605.50 | 67,022.16 | 27.94 | 13,458.30 | 3.70 | 2,216 | 10.98 | 49.02 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
18.55 %
Net Income Growth
20.45 %
Cash Flow Change
112.02 %
ROE
0.98 %
ROCE
7.64 %
EBITDA Margin (Avg.)
9.06 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 9,047 | 10,551 | 15,221 | 18,065 | 23,483 | 23,687 | 23,885 | 27,795 | 25,756 | 29,281 | 37,202 |
| Fixed Assets | 3,352 | 3,748 | 5,755 | 6,483 | 12,164 | 12,231 | 12,133 | 12,189 | 11,521 | 12,369 | 13,134 |
| Current Assets | 4,227 | 4,280 | 6,022 | 8,230 | 8,498 | 8,715 | 8,716 | 12,095 | 10,008 | 11,420 | 17,046 |
| Capital Work in Progress | 798 | 951 | 1,543 | 1,527 | 837 | 742 | 783 | 726 | 1,201 | 2,423 | 2,692 |
| Investments | 121 | 416 | 435 | 746 | 674 | 765 | 830 | 3,288 | 1,547 | 1,221 | 6,408 |
| Other Assets | 4,776 | 5,436 | 7,488 | 9,310 | 9,809 | 9,950 | 10,139 | 11,593 | 11,488 | 13,269 | 14,968 |
| Total Liabilities | 9,047 | 10,551 | 15,221 | 18,065 | 23,483 | 23,687 | 23,885 | 27,795 | 25,756 | 29,281 | 37,202 |
| Current Liabilities | 3,285 | 3,461 | 5,306 | 6,083 | 7,343 | 8,269 | 7,861 | 7,827 | 5,527 | 5,340 | 9,042 |
| Non Current Liabilities | 1,342 | 1,255 | 2,799 | 3,047 | 4,461 | 3,707 | 1,094 | 915 | 541 | 1,840 | 1,802 |
| Total Equity | 4,421 | 5,835 | 7,116 | 8,936 | 11,679 | 11,710 | 14,930 | 19,054 | 19,688 | 22,102 | 26,358 |
| Reserve & Surplus | 4,149 | 5,597 | 6,858 | 8,642 | 10,284 | 10,273 | 12,890 | 16,897 | 17,415 | 19,729 | 23,853 |
| Share Capital | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 101 | 101 | 101 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 178 | 99 | 756 | -3 | -811 | 399 | -91 | 219 | -170 | -75 | 414 |
| Investing Activities | -465 | -860 | -2,872 | -974 | -3,977 | -1,004 | -837 | -1,018 | 1,542 | -1,492 | -8,377 |
| Operating Activities | 994 | 1,894 | 1,312 | 919 | 1,282 | 2,932 | 3,294 | 2,105 | 2,689 | 3,196 | 6,777 |
| Financing Activities | -351 | -935 | 2,316 | 52 | 1,885 | -1,528 | -2,548 | -868 | -4,400 | -1,779 | 2,014 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 74.88 % | 74.88 % | 74.88 % | 74.88 % | 74.88 % | 74.88 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.99 % | 74.99 % | 74.99 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 5.72 % | 5.59 % | 7.52 % | 7.53 % | 7.32 % | 7.13 % | 7.34 % |
| DIIs | 11.11 % | 10.43 % | 11.22 % | 11.78 % | 12.78 % | 11.92 % | 12.94 % | 13.69 % | 13.60 % | 13.23 % | 13.09 % | 12.79 % | 12.63 % | 12.64 % | 10.65 % | 10.65 % | 11.01 % | 11.13 % | 10.86 % |
| Government | 0.19 % | 0.07 % | 0.07 % | 0.07 % | 0.08 % | 0.08 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 6.16 % | 7.31 % | 7.38 % | 7.40 % | 7.81 % | 8.02 % | 7.60 % | 7.04 % | 6.42 % | 5.97 % | 5.67 % | 5.60 % | 5.29 % | 5.37 % | 5.48 % | 5.47 % | 5.41 % | 5.46 % | 5.49 % |
| Others | 7.66 % | 7.32 % | 6.44 % | 5.87 % | 4.46 % | 5.11 % | 4.48 % | 4.29 % | 5.00 % | 5.82 % | 6.26 % | 6.63 % | 1.38 % | 1.43 % | 1.37 % | 1.36 % | 1.28 % | 1.28 % | 1.32 % |
| No of Share Holders | 0 | 2,23,384 | 3,31,155 | 3,51,595 | 3,70,931 | 4,08,017 | 4,55,624 | 4,08,231 | 3,70,396 | 3,11,764 | 2,97,953 | 3,06,495 | 2,94,324 | 3,36,309 | 3,70,863 | 3,65,356 | 3,71,619 | 3,86,127 | 3,96,105 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 3.2 | 3.5 | 3.5 | 3.5 | 3.5 | 2.5 | 6 | 3 | 11 |
| Dividend Yield (%) | 0.00 | 0.85 | 1.01 | 1.31 | 0.79 | 1 | 0.51 | 0.6 | 0.34 | 1.18 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 30 Jul 2021 |  Dividend | ₹ 3.50 /share | 28 Jul 2021 | 628.10 | 571.90 |
| 29 Jul 2022 | Dividend | ₹ 2.50 /share | 28 Jul 2022 | 338.75 | 349.60 |
| 28 Jul 2023 | Dividend | ₹ 6.00 /share | 28 Jul 2023 | 518.80 | 649.50 |
| 29 Feb 2024 |  Buyback | 1005:600 | 23 Feb 2024 | 953.75 | 932.80 |
| 26 Jul 2024 | Dividend | ₹ 3.00 /share | 26 Jul 2024 | 1,009.00 | 1,205.80 |
| 09 Aug 2024 |  Annual General Meeting | NA | 09 Aug 2024 | 1,009.00 | 1,279.40 |
| 12 Nov 2024 |  Quarterly Result Announcement | NA | 12 Nov 2024 | 1,002.20 | 968.55 |
| 05 Feb 2025 | Quarterly Result Announcement | NA | 05 Feb 2025 | 995.50 | 974.00 |
| 20 May 2025 | Quarterly Result Announcement | NA | 20 May 2025 | 873.70 | 911.40 |
| 25 Jul 2025 | Dividend | ₹ 11.00 /share | 25 Jul 2025 | 902.70 | 971.05 |
| 12 Aug 2025 | Quarterly Result Announcement | NA | 12 Aug 2025 | 969.80 | 955.50 |
| 12 Aug 2025 | Annual General Meeting | NA | 12 Aug 2025 | 911.40 | 955.50 |
| 06 Nov 2025 | Quarterly Result Announcement | NA | 06 Nov 2025 | 1,001.35 | 971.70 |
Announcements
Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot
2 days ago
2 days ago Shareholder Meeting / Postal Ballot-Scrutinizer"s Report2 days ago
2 days agoShareholder Meeting / Postal Ballot-Outcome of Postal_Ballot2 days ago
2 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release5 days ago
5 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release5 days ago
5 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 27, 2025
Nov 27, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 26, 2025
Nov 26, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 25, 2025
Nov 25, 2025Announcement under Regulation 30 (LODR)-Investor PresentationNov 25, 2025
Nov 25, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 22, 2025
Nov 22, 2025General UpdateNov 19, 2025
Nov 19, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 18, 2025
Nov 18, 2025Disclosure Under SEBI (Prohibition Of Insider Trading) Regulations 2015Nov 17, 2025
Nov 17, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 14, 2025
Nov 14, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 14, 2025
Nov 14, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 13, 2025
Nov 13, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 13, 2025
Nov 13, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 13, 2025
Nov 13, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 13, 2025
Nov 13, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 13, 2025
Nov 13, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 12, 2025
Nov 12, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotNov 11, 2025
Nov 11, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 11, 2025
Nov 11, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 07, 2025
Nov 07, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 07, 2025
Nov 07, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 06, 2025
Nov 06, 2025Announcement under Regulation 30 (LODR)-Investor PresentationNov 06, 2025
Nov 06, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 06, 2025
Nov 06, 2025Announcement under Regulation 30 (LODR)-Raising of FundsNov 06, 2025
Nov 06, 2025Board Meeting Outcome for Outcome Of Board MeetingNov 06, 2025
Nov 06, 2025Unaudited Financial Results For The Quarter And Half Year Ended On September 30 2025Nov 06, 2025
Nov 06, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 06, 2025
Nov 06, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 05, 2025
Nov 05, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 04, 2025
Nov 04, 2025Update on board meetingNov 03, 2025
Nov 03, 2025Demand Notice From GST DepartmentNov 01, 2025
Nov 01, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 29, 2025
Oct 29, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 29, 2025
Oct 29, 2025Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter / Half Year Ended On September 30 2025.Oct 29, 2025
Oct 29, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionOct 26, 2025
Oct 26, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 24, 2025
Oct 24, 2025UpdateOct 17, 2025
Oct 17, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 14, 2025
Oct 14, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 09, 2025
Oct 09, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 06, 2025
Oct 06, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 06, 2025
Oct 06, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 04, 2025
Oct 04, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 01, 2025
Oct 01, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionSep 30, 2025
Sep 30, 2025Mutual Fund Holdings
Parag Parikh Flexi Cap Fund Direct-Growth 
Kotak Arbitrage Fund Direct-Growth 
ICICI Prudential India Opportunities Fund Direct - Growth 
360 ONE Quant Fund Direct - Growth 
Invesco India Arbitrage Fund Direct-Growth 
Tata Arbitrage Fund Direct - Growth 
Edelweiss Business Cycle Fund Direct-Growth 
Nippon India Arbitrage Fund Direct-Growth 
Sundaram Multi-Factor Fund Direct-Growth 
Bandhan Multi-Factor Fund Direct - Growth 
SBI Arbitrage Opportunities Fund Direct-Growth 
Motilal Oswal Quant Fund Direct-Growth 
Navi Aggressive Hybrid Fund Direct - Growth 
Mirae Asset Arbitrage Fund Direct - Growth 
Baroda BNP Paribas Value Fund Direct - Growth 
UTI Arbitrage Fund Direct-Growth 
HDFC Arbitrage Fund Wholesale Direct-Growth 
The Wealth Company Arbitrage Fund Direct-Growth Technical Indicators
RSI(14)
Neutral 42.49
ATR(14)
Less Volatile 14.68
STOCH(9,6)
Neutral 29.73
STOCH RSI(14)
Neutral 48.71
MACD(12,26)
Bullish 1.11
ADX(14)
Weak Trend 14.93
UO(9)
Bearish 38.40
ROC(12)
Downtrend And Accelerating -1.21
WillR(14)
Neutral -54.28
About Zydus Life Science
Zydus Lifesciences Limited is an Indian global life sciences company that discovers, develops, manufactures, and markets healthcare therapies. Its product portfolio includes active pharmaceutical ingredients, human formulations, animal health products, and wellness products. The company operates in pharmaceuticals, covering human and veterinary formulations, bulk drugs, diagnostics, herbal products, skin care, and over-the-counter products. Zydus has a global presence, marketing products in the United States, India, Europe, and emerging markets. Key products include Lipaglyn, Bilypsa, Ujvira, Exemptia, Vivitra, and Bryxta, covering areas such as oncology, autoimmune diseases, nephrology, and infectious illnesses. The company has manufacturing facilities in various Indian states and has made several strategic acquisitions and partnerships to expand its product range and market presence.
Listing Date
27 Apr, 2000(25 Years,
-12 days)
Website
Chairperson NamePankaj R Patel
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
